ArticleBlood2011
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.The Journal of experimental medicine · 2020Trial
- Long-term outcomes of helper peptide vaccination for metastatic melanoma.Annals of surgery · 2015Trial
- BDCA2 plays a central role in the binding, internalization and response of plasmacytoid dendritic cells to vidutolimod.Frontiers in immunology · 2026Article
- Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions.Oncology research · 2025Review
- Engineering bioactive mineralized tumor cells for tumor immunotherapy.Frontiers in bioengineering and biotechnology · 2025Article
- Article
- Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.Biomolecules · 2022Review
- Therapeutic vaccines for aggressive B-cell lymphoma.Leukemia & lymphoma · 2020Article
- Programmable multistage drug delivery to lymph nodes.Nature nanotechnology · 2020Article
- Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo.Cell stem cell · 2018Article
- Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.Scientific reports · 2017Article
- Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.Bioconjugate chemistry · 2017Article
- Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.Cancer immunology, immunotherapy : CII · 2017Review
- Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Seminars in oncology · 2015Review
- Article
- Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors.Cancer immunology, immunotherapy : CII · 2015Article
- Lymphoma Immunotherapy: Current Status.Frontiers in immunology · 2015Review
- TLR9 is critical for glioma stem cell maintenance and targeting.Cancer research · 2014Article
- Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation.Chemical communications (Cambridge, England) · 2013Article
- Cancer vaccines and T cell therapy.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
We designed a whole tumor cell vaccine by "loading" lymphoma tumor cells with CG-enriched oligodeoxynucleotide (CpG), a ligand for the Toll-like receptor 9 (TLR9). CpG-loaded tumor cells were phagocytosed, delivering both tumor antigen(s) and the immunostimulatory CpG molecule to antigen-presenting cells (APCs). These APCs then expressed increased levels of costimulatory molecules and induced T-cell immunity. TLR9 was required in the APCs but not in the CpG-loaded tumor cell. We demonstrate that T cells induced by this vaccine are effective in adoptive cellular therapy for lymphoma. T cells from vaccinated mice transferred into irradiated, syngeneic recipients protected against subsequent lymphoma challenge and, remarkably, led to regression of large and established tumors. This therapeutic effect could be transferred by CD4(+) but not by CD8(+) T cells. A CpG-loaded whole-cell vaccination is practical and has strong potential for translation to the clinical setting. It is currently being tested in a clinical trial of adoptive immunotherapy for mantle-cell lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.